Latest News
AI Conjures Up Potential New Antibody Drugs in a Matter of Months
Test-Time Scaling Unlocks a Leap Forward in De Novo Antibody Design
De novo design of hundreds of functional GPCR-targeting antibodies enabled by scaling test-time compute
Designed by AI: the future of antibody drugs
Scratch That? De Novo Antibody Design Enters the AI Drug Discovery Toolbox
Test-Time Scaling Improves Speed and Success of AI-Based Antibody Design
Two biotechs say they’re using AI to conjure drugs from scratch. Their documents suggest otherwise
Better antibodies by engineering targets, not engineering antibodies (Nabla Bio)
With all eyes on AI-protein design, Nabla says it can model therapeutic antibodies
Nabla Bio Moves Closer to AI Created Antibodies
De novo design of antibodies enabled by Joint Atomic Modeling
De novo design of epitope-specific antibodies against soluble and multipass membrane proteins with high specificity, developability, and function
Nabla Bio Advances Generative Protein Design with $26M Series A Funding